comparemela.com

Page 2 - Harmony Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Wakix Patent Challenge Rejected by US Patent Office

The US Patent Office has denied a Petition for Reexamination concerning a patent covering the active ingredient in Wakix (pitolisant). 

Cantor Fitzgerald Brokers Cut Earnings Estimates for Harmony Biosciences Holdings, Inc (NASDAQ:HRMY)

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) – Cantor Fitzgerald decreased their FY2023 earnings estimates for shares of Harmony Biosciences in a research note issued to investors on Wednesday, August 2nd. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will post earnings of $2.31 per share for the year, down from their […]

Harmony Biosciences (NASDAQ:HRMY) & Astria Therapeutics (NASDAQ:ATXS) Head-To-Head Review

Astria Therapeutics (NASDAQ:ATXS – Get Free Report) and Harmony Biosciences (NASDAQ:HRMY – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership. Risk and Volatility Astria Therapeutics has a […]

Financial Contrast: Harmony Biosciences (NASDAQ:HRMY) vs Alterity Therapeutics (NASDAQ:ATHE)

Alterity Therapeutics (NASDAQ:ATHE – Get Rating) and Harmony Biosciences (NASDAQ:HRMY – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership. Volatility and Risk Alterity Therapeutics has a beta of 1.2, […]

Cantor Fitzgerald Weighs in on Harmony Biosciences Holdings, Inc s FY2023 Earnings (NASDAQ:HRMY)

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Rating) – Cantor Fitzgerald raised their FY2023 EPS estimates for shares of Harmony Biosciences in a note issued to investors on Wednesday, May 3rd. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will post earnings per share of $2.36 for the year, up from their previous […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.